BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. DESIGN, SETTING, AND PARTICIPANTS: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. INTERVENTION: All patients were treated with RNU. MEASUREMENTS: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. RESULTS AND LIMITATIONS: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p=0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2). On multivariate analysis, pathologic stage (p<0.0001) and nodal status (p=0.01) were associated with worse CSS. This study is limited by its retrospective nature. CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious. OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC. DESIGN, SETTING, AND PARTICIPANTS: Prospectively collected data were retrospectively reviewed from 324 consecutive patients treated with RNU between 1995 and 2008 at a single tertiary referral center. Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded. This left 253 patients for analysis. Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor. Recurrences in the bladder only, in nonbladder sites, and in any site were analyzed. INTERVENTION: All patients were treated with RNU. MEASUREMENTS: Recurrence-free survival and CSS probabilities were estimated using Kaplan-Meier and Cox regression analyses. RESULTS AND LIMITATIONS: Median follow-up for survivors was 48 mo. The 5-yr recurrence-free probability (including bladder recurrence) and CSS estimates were 32% and 78%, respectively. On multivariable analysis, pathologic stage was the only predictor for disease recurrence (p=0.01). Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18). On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2). On multivariate analysis, pathologic stage (p<0.0001) and nodal status (p=0.01) were associated with worse CSS. This study is limited by its retrospective nature. CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors: Eiji Kikuchi; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Shuji Mikami; Yair Lotan; Mesut Remzi; Christian Bolenz; Cord Langner; Alon Weizer; Francesco Montorsi; Karim Bensalah; Theresa M Koppie; Mario I Fernández; Jay D Raman; Wassim Kassouf; Christopher G Wood; Nazareno Suardi; Mototsugu Oya; Shahrokh F Shariat Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Hendrik Isbarn; Claudio Jeldres; Shahrokh F Shariat; Daniel Liberman; Maxine Sun; Giovanni Lughezzani; Hugues Widmer; Philippe Arjane; Daniel Pharand; Margit Fisch; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni Journal: BJU Int Date: 2011-06-01 Impact factor: 5.588
Authors: M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat Journal: Urologe A Date: 2012-09 Impact factor: 0.639
Authors: Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat Journal: World J Urol Date: 2016-04-21 Impact factor: 4.226
Authors: Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Nat Rev Urol Date: 2011-07-05 Impact factor: 14.432
Authors: Laura-Maria Krabbe; Aditya Bagrodia; Mary E Westerman; Bishoy A Gayed; Ahmed Q Haddad; Arthur I Sagalowsky; Shahrokh F Shariat; Payal Kapur; Yair Lotan; Vitaly Margulis Journal: World J Urol Date: 2015-05-20 Impact factor: 4.226
Authors: Francesco Soria; Shahrokh F Shariat; Seth P Lerner; Hans-Martin Fritsche; Michael Rink; Wassim Kassouf; Philippe E Spiess; Yair Lotan; Dingwei Ye; Mario I Fernández; Eiji Kikuchi; Daher C Chade; Marko Babjuk; Arthur P Grollman; George N Thalmann Journal: World J Urol Date: 2016-09-07 Impact factor: 4.226